Amantadine and Fatal Events in Patients With Chronic Kidney Disease: Analysis of the Japanese Adverse Event Report Database

Abstract

Get full access to this article

View all access options for this article.

References

Poewe

Mahlknecht

Pharmacologic treatment of motor symptoms associated with Parkinson disease. Neurol Clin. 2020;38:255-267. doi:10.1016/j.ncl.2019.12.002

Müller

Möhr

JD.

Recent clinical advances in pharmacotherapy for levodopa-induced dyskinesia. Drugs. 2019;79:1367-1374. doi:10.1007/s40265-019-01170-5

Giacino

Whyte

Bagiella

, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012;366:819-826. doi:10.1056/NEJMoa1102609

deVries

Dentiste

Handiwala

Jacobs

Bioavailability and pharmacokinetics of once-daily amantadine extended-release tablets in healthy volunteers: results from three randomized, crossover, open-label, phase 1 studies. Neurol Ther. 2019;8:449-460. doi:10.1007/s40120-019-0144-1

Cedarbaum

JM.

Clinical pharmacokinetics of anti-Parkinsonian drugs. Clin Pharmacokinet. 1987;13:141-178. doi:10.2165/00003088-198713030-00002

Somani

Degelau

Cooper

Guay

DRP

Ehresman

Zaske

Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents. Pharmacotherapy. 1991;11:460-466. doi:10.1002/j.1875-9114.1991.tb02661.x

Cattoni

Parekh

Acute respiratory distress syndrome: a rare presentation of amantadine toxicity. Am J Case Rep. 2014;15:1-3. doi:10.12659/AJCR.889931

Cook

Dermer

McGurk

Fatal overdose with amantadine. Can J Psychiatry. 1986;31:757-758. doi:10.1177/070674378603100814

Keyser

Karl

Nafziger

Bertino

Jr.

Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med. 2000;160:1485-1488. doi:10.1001/archinte.160.10.1485